₹ 109.70
-0.70 (-0.63%)Open
109.7High
109.7Low
109.7Prev Close
110.4P/E
15.59Median P/E
31.6P/B
1.19Median P/B
4.82Market Cap
11.49BPEG
2.82Div.Yield
0.45Bid
109.70Ask
111.00Large Cap
11.49B Mkt. Cap.Volatility
-Beta
0.71Genie Says
Influencer Count
-Days | BSE | NSE |
---|
5 | 109.78 | 109.73 |
10 | 110.32 | 110.26 |
20 | 113.82 | 113.83 |
50 | 114.33 | 114.34 |
100 | 119.05 | 119.07 |
300 | 111.42 | 111.43 |
BSE
506197NSE
BLISSGVSISIN
INE416D01022Bliss GVS Pharma Limited is engaged in developing, manufacturing, and marketing pharmaceutical formulations. The Company’s product categories include pharma products and other healthcare products. Its pharma products include pharma products include capsules, creams, gels, ointments, dry powder for injection, effervescent tablets, eye/ear drops, nasal solution, lotions, lozenges, soft gelatine capsules and syrups. The Company’s other healthcare products include balm, nasal inhaler, solution, soap, vaginal wash, roll on, shampoo, powder, spray, and petroleum jelly. Its brands include ANOMEX, ANOMEX DS, CONLAX 5/10, G - ALFENAC 100, GACET 80/125/170/250/500/1G, GMETH - 50/100, GSUNATE - 50/100/200, GVCAM - 7.5/15, GV-SOFT 1/2/3/4 G, LOFNAC - 12.5/25/50/100, MEFINOL, MELANEZ, MENINA - 25/100, TYRIDOL, VIGOTAMIN, COMIT 50, BG - CLIND, VAGID CL, ECOZOLE, GVGYL 500, GYNANFORT, GVGYL N, KLOVINAL, LONART, LONART FORTE, LONART Dispersible, FINMOL, GACET-500, and DOXYCYCLINE.
Deepak Sawant
Chief Financial OfficerAditi Bhatt
Chief Compliance Officer, Company SecretaryGagan Sharma
Managing Director, Executive DirectorShruti Rao
Whole-Time DirectorVibha Sharma
Whole-Time Director